China’s Diabetes Race Heats Up As Novo Pins Hopes On Human Insulin EDL Inclusion; Lilly Calls For Faster Coverage
This article was originally published in PharmAsia News
Executive Summary
As Novo, Sanofi and Lilly anxiously await listings for diabetes drugs on China’s Essential Drug List, most are readying themselves with patient education efforts to boost patient numbers and compliance.
You may also be interested in...
Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 1 of 2)
Sanofi SA China Pharmaceutical Operations General Manager Fabrice Baschiera spent more than eight years in Asia working for Sanofi's Asia operations in South Korea, Thailand and Vietnam before he moved to China last August.
Lilly/BI Eye Diabetes Leadership In Expansive Risk-Sharing Collaboration
The two drug makers will jointly develop four diabetes drugs: two oral agents from Boehringer Ingelheim and two basal insulin analogues from Lilly.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.